Abstract
Except for few cases, chemotherapeutic toxicity is in general influenced by multiple genetic factors and nongenetic factors including age, sex and drug-drug interactions. The manifestations of adverse drug reactions differ between men and women. In particular, women experience greater toxicity from certain chemotherapeutic drugs than men. Sexrelated factors are likely to play an increasing role in drug development and therapeutic decision-making in the future. The sex-selective toxicity could be attributed to sex-related differences in pharmacokinetic and pharmacodynamic properties of these drugs. Systematic pharmacogenomic investigation into sex difference in chemotherapeutic toxicity potentially presents an opportunity to assess the effects of multiple genetic factors or gene networks on sex-related differences in the toxicity of anti-cancer drugs. A thorough understanding of the interactions between sex, drug and gene will provide valuable insights in assessing the susceptibility of an individual to chemotherapy-induced toxicity, predicting the sex-related effects for any anticancer drug and ultimately achieving the goal of personalized cancer therapy.
Keywords: Sex difference, pharmacogenomics, chemotherapeutic toxicity, personalized drug therapy
Current Drug Discovery Technologies
Title: Pharmacogenomics of Sex Difference in Chemotherapeutic Toxicity
Volume: 4 Issue: 1
Author(s): Jeffrey Wang and Ying Huang
Affiliation:
Keywords: Sex difference, pharmacogenomics, chemotherapeutic toxicity, personalized drug therapy
Abstract: Except for few cases, chemotherapeutic toxicity is in general influenced by multiple genetic factors and nongenetic factors including age, sex and drug-drug interactions. The manifestations of adverse drug reactions differ between men and women. In particular, women experience greater toxicity from certain chemotherapeutic drugs than men. Sexrelated factors are likely to play an increasing role in drug development and therapeutic decision-making in the future. The sex-selective toxicity could be attributed to sex-related differences in pharmacokinetic and pharmacodynamic properties of these drugs. Systematic pharmacogenomic investigation into sex difference in chemotherapeutic toxicity potentially presents an opportunity to assess the effects of multiple genetic factors or gene networks on sex-related differences in the toxicity of anti-cancer drugs. A thorough understanding of the interactions between sex, drug and gene will provide valuable insights in assessing the susceptibility of an individual to chemotherapy-induced toxicity, predicting the sex-related effects for any anticancer drug and ultimately achieving the goal of personalized cancer therapy.
Export Options
About this article
Cite this article as:
Jeffrey Wang and Ying Huang , Pharmacogenomics of Sex Difference in Chemotherapeutic Toxicity, Current Drug Discovery Technologies 2007; 4 (1) . https://dx.doi.org/10.2174/157016307781115485
DOI https://dx.doi.org/10.2174/157016307781115485 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry Biomedical Exploitation of Self Assembled Peptide Based Nanostructures
Current Protein & Peptide Science Human Amnion–Derived Cells as a Reliable Source of Stem Cells
Current Molecular Medicine Jaridonin, a Novel Ent-Kaurene Diterpenoid from Isodon rubescens, Inducing Apoptosis via Production of Reactive Oxygen Species in Esophageal Cancer Cells
Current Cancer Drug Targets Aromatase Inhibitors Evolution as Potential Class of Drugs in the Treatment of Postmenopausal Breast Cancer Women
Mini-Reviews in Medicinal Chemistry A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Antibiotics Delay Wound Healing: an Effect Reversed by Co-Administering TLR 7 and 9 Ligands
Current Angiogenesis (Discontinued) MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Non-Invasive Approaches to Visualize the Endothelin Axis In Vivo Using State-of-the-Art Molecular Imaging Modalities
Mini-Reviews in Medicinal Chemistry Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO)
Current Radiopharmaceuticals An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors
Current Medicinal Chemistry Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Drug Metabolism Letters Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Structural Investigation of Proapoptotic Peptide by Cd and Nmr Spectroscopy
Protein & Peptide Letters Eradicating the Roots: Advanced Therapeutic Approaches Targeting Breast Cancer Stem Cells
Current Pharmaceutical Design Antimicrobial Effect of Garlic (Allium sativum)
Recent Patents on Anti-Infective Drug Discovery Acute Kidney Injury: Turning the Tide
Current Drug Targets Small Animal Computed Tomography Imaging
Current Medical Imaging